Tuesday, September 29, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Regulatorysemaglutidetirzepatideretatrutidefdasupply chain

Twenty state attorneys general press Rubio on Chinese GLP-1 ingredients

The letter cites an FDA warning letter to Harbin Jixianglong, which repackaged non-Green List semaglutide and altered manufacturing dates before US distribution.

DO
By Daniel Okafor · Regulatory Correspondent
Sep 25 21:05 ETSource: Picayune Item

The wire

  1. 01Mississippi AG Lynn Fitch and 19 other attorneys general wrote Secretary of State and National Security Advisor Marco Rubio urging safeguards against Chinese-sourced active ingredients used in compounded semaglutide, tirzepatide and retatrutide.
  2. 02The letter targets the API supply chain behind compounded GLP-1s and cosmetic and weight-loss peptides, a direct concern for 503A pharmacies and telehealth prescribers sourcing overseas material.
  3. 03FDA authorized a Green List of verified suppliers in September 2025, but the Harbin case shows listing alone did not prevent relabelled product from reaching the US market.

From the source

AG Fitch urges NSC to protect GLP-1 Drugs

Ahead of Xi Jinping’s meeting with the President, Attorney General Lynn Fitch joined a 20-state letter to Secretary of State and National Security Advisor Marco Rubio urging the administration to guard against Chinese efforts to introduce low-quality and unsafe pharmaceutical ingredients to the U.S. pharmaceutical supply chain given recent reports of Chinese-source businesses circumventing America

Read at picayuneitem.com
PeptiPrescribed peptides from $99/moSee all →